^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Prosigna™ Breast Cancer Prognostic Gene Signature Assay

Type:
FDA Approved
Related tests:
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test) uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test analyzes the activity of 50 genes known as the PAM50 gene signature, along with clinical-pathological features, and can provide a hormone-receptor positive early breast cancer patient and her physician with a prognostic score indicating the probability of cancer recurrence during the next 10 years. Outside of the United States, it is also utilized to provide PAM50 molecular subtype information. The Prosigna test is FDA 510(k) cleared in the United States for use on the nCounter® Dx Analysis System
Cancer:
Breast Cancer
Gene:
ER (Estrogen receptor), HER-2 (Human epidermal growth factor receptor 2), PGR (Progesterone receptor)
Method:
Multiplex RT- PCR
Approvals
Date
Cancer
Gene
Drug
By
09/06/13
FDA
Confirmatory trial(s)